<DOC>
	<DOCNO>NCT00739934</DOCNO>
	<brief_summary>In study measure concentration drug call voriconazole use fight infection cause fungus child usually cancer patient immune system . Since know dose adult , think know match dos young patient age 2 12 year old , compare amount drug go system know work adult . We give drug needle directly blood , day later stop give drug mouth . Meanwhile , draw little bit blood certain time measure drug .</brief_summary>
	<brief_title>Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidemia</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Male female 2 &lt; 12 year age . Require treatment prevention systemic fungal infection . Expected develop neutropenia ( ANC &lt; 500 cells/Î¼L ) last 10 day follow chemotherapy . Anticipated live 3 month . Evidence clinically significant liver renal function abnormality cardiac arrhythmia , hypokalemia , hypomagnesemia hypocalcemia . Documented bacterial viral infection respond appropriate treatment . Hypersensitivity severe intolerance azole antifungal agent . Receiving azoles drug prohibit voriconazole label associate .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Open-Label</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Intravenous oral switch</keyword>
	<keyword>Safety</keyword>
	<keyword>Voriconazole</keyword>
	<keyword>Immunocompromise</keyword>
	<keyword>Children</keyword>
	<keyword>High Risk For Systemic Fungal Infection .</keyword>
</DOC>